BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6323189)

  • 41. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system.
    Iigo M; Kuretani K; Hoshi A
    Cancer Res; 1983 Dec; 43(12 Pt 1):5687-94. PubMed ID: 6640523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
    Rose WC; Schurig JE; Huftalen JB; Bradner WT
    Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399
    [No Abstract]   [Full Text] [Related]  

  • 43. Schedule-dependent cytotoxicity of 5-fluorouracil in mice.
    Santelli G; Valeriote F
    J Natl Cancer Inst; 1986 Jan; 76(1):159-64. PubMed ID: 3455738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
    Stolfi RL; Sawyer RC; Martin DS
    Cancer Res; 1987 Jan; 47(1):16-20. PubMed ID: 3791203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
    Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
    Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.
    Waud WR; Gilbert KS; Secrist JA
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):399-403. PubMed ID: 21069340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
    Li LH; Wallace TL; Richard KA; Tracey DE
    Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antileukemic activity of 4-demethoxydaunorubicin in mice.
    Casazza AM; Pratesi G; Giuliani F; Di Marco A
    Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
    Mabel JA; Wodinsky I
    Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
    Kataoka T; Akahori Y; Sakurai Y
    Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
    Sladek NE; Landkamer GJ
    Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate.
    Inaba M; Fukui M; Yoshida N; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Mar; 42(3):1103-6. PubMed ID: 6277474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of cimetidine combination with cyclophosphamide in transplanted murine tumors.
    Khandalekar DD; Ganu UK; Gokhale SV
    Indian J Physiol Pharmacol; 1989; 33(3):171-4. PubMed ID: 2592043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
    Zaharko D; Plowman J; Waud W; Dykes D; Malspeis L
    Cancer Res; 1992 Jul; 52(13):3604-9. PubMed ID: 1617631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of biological response modifier sulfoethylated (1 --> 3)-beta-D-glycan on the experimental leukemia in mice].
    Khalikova TA; Korolenko TA
    Eksp Klin Farmakol; 2006; 69(5):39-43. PubMed ID: 17153965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancement of antitumor activity of 5-fluorouracil by ribothymidine.
    Tezuka M; Chiba Y; Okada S; Tamemasa O
    J Pharmacobiodyn; 1986 Aug; 9(8):683-7. PubMed ID: 3783412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The antineoplastic effect of violamycins and lambdamycin in experimental leukemias].
    Gutsche W; Jungstand W; Wohlrabe K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):647-51. PubMed ID: 6172328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.